Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Casma: Tailoring autophagy targets to indications

How Third Rock portfolio company Casma is evaluating the entire autophagy pathway for a broad swath of diseases

Sandi Wong, Staff Writer
June 20, 2019 9:17 PM UTC

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases.

According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared by seemingly disparate diseases, including Parkinson's disease, non-alcoholic steatohepatitis (NASH) and lysosomal storage disorder Pompe disease. The commonality of substrate accumulation presents the cellular recycling pathway as a common therapeutic target...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Casma Therapeutics Inc.

Third Rock Ventures

BCIQ Target Profiles

Mucolipin 1 (TRPML1) (MCOLN1)